For the quarter ended December 2023, Quest Diagnostics (DGX) reported revenue of $2.29 billion, down 1.9% over the same period last year. EPS came in at $2.15, compared to $1.98 in the year-ago quarter.The reported revenue represents a surprise of +1.80% over the Zacks Consensus Estimate of $2.25 billion. With the consensus EPS estimate being $2.14, the EPS surprise was +0.47%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Quest Diagnostics Incorporated’s (DGX) fourth-quarter 2023 adjusted earnings per share (EPS) of $2.15 beat the Zacks Consensus Estimate by 0.5%. The metric also surpassed the year-ago adjusted figure by 8.6%.Certain one-time expenses, like the ones related to amortization expenses, certain restructuring and integration charges, other expenses and excess tax benefits associated with stock-based compensations, were excluded from the quarter’s adjusted figures.GAAP earnings came in at $1.70 per share compared ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.15 per share, beating the Zacks Consensus Estimate of $2.14 per share. This compares to earnings of $1.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.47%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.19 per share when it actually produced earnings of $2.22, delivering a surprise of 1.37%.Over the last four qua ...

SECAUCUS, N.J., Jan. 31, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year.  Fortune's World's Most Admired Companies recognition is based on nine criteria of corporate reputation, from innovation and quality of management and products, to social responsibility and people management. "I'm grateful to our dedica ...

Quest Diagnostics' (DGX) wholly-owned subsidiary Haystack Oncology recently formed a research collaboration with TriSalus Life Sciences. Per the deal, Haystack Oncology, the developer of Haystack MRD, a best-in-class personalized minimal residual disease (MRD) technology, plans to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.This research collaboration holds the pro ...

One of the deadliest diseases in recent times, cancer accounts for approximately 10 million annual deaths worldwide or every one in six people (as revealed by WHO). This hugely increasing incidence of cancer has fueled the demand for oncology across the globe quite enormously. Per a recent report, the $305.1 billion oncology market is currently undergoing a revolutionary change, driven by unprecedented advances in diagnoses and treatments.As cancer research progresses and new technologies emerge, investing ...

The year 2023 has experienced a volatile global economic condition as in the initial months, many sectors rebounded with the opening of lockdowns in several regions. The implementation of bold fiscal stimuli and relief initiatives to spur economic growth positively impacted investment trends globally. However, pressures in the form of inflation, corporate restructuring, difficulties with demand forecasting and geo-political tensions (particularly the Russia-Ukraine, Isael-Hamas and Taiwan-China conflicts) h ...

Quest Diagnostics (DGX) recently announced a collaboration with the leading health and fitness platform, Fitbit, to study the potential of wearable devices to improve metabolic health. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways to combine and analyze data for the enhanced assessment and management of metabolic health and aid in disease prevention.The latest ...

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives. That’s because there’s currently no good screening procedures for many types of cancers, such as pancreatic cancer and lung cancer. And by the time the tumors cause symptoms, it’s usually too late to save the patients’ lives. Also noteworthy is that these diagnostics, or multi-cancer early detection tests (MCEDs), can save hospitals and health insurers a great deal of mo ...

SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 1, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.    The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0 ...